

Application Serial Number 10/579219
Response to Office Action dated 01/11/2008


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.


Listing of Claims:

1. – 5. (Cancelled)

6. (Currently amended) Derivatives of compounds Garcinol and Isogarcinol of




~~FORMULA 1~~




FORMULA 2

Application Serial Number 10/579219
 Response to Office Action dated 01/11/2008



FORMULA I



FORMULA II

respectively, wherein R1, R2 and R3, substituents of Garcinol, and R4 and R5, substituents of Isogarcinol, are selected from a group ~~comprising~~ consisting of Θ -Methoxy, Θ -Ethoxy, Θ -Isopropoxy, Θ -Allyloxy, Θ -Butoxy, Θ -t-Butoxy, Θ -Pentoxy, Θ -Hexyloxy, O-CH₂-COOH, O-CO-CH₂-~~CH~~Cl, O-SO₂-CH₃, and Θ -O-CH₂-CHOH-CH₃.

7. (Currently amended) A process for preparation of derivatives of compound ~~g~~G~~arcinol or~~ arcinol and Isogarcinol of formula I and II, respectively, said process comprising steps of reacting ~~g~~G~~arcinol or~~ arcinol with halo compounds to obtain the derivatives with the selected substituents of R1, R2, R3, R4 and R5, at temperature ranging between

Application Serial Number 10/579219
Response to Office Action dated 01/11/2008

30 – 40°C under alkaline conditions in presence of organic solvents, and purifying
~~followed by purification to obtain the derivatives.~~

8. (Currently Amended) ~~A~~The process for preparation as claimed in claim 7,
wherein the reacting process is carrying the reaction carried in presence of at least one of
alkaline hydroxides or alkaline carbonates.


9. (Currently Amended) ~~A~~The process for preparation as claimed in claim 7,
wherein the compounds Garcinol and Isogarcinol are in equimolar concentration.

10. (Currently Amended) ~~A~~The process for preparation as claimed in claim 7,
wherein the organic solvent is selected from a group comprisingconsisting of acetone,
chloroform, MDC and EDC.


11. (Currently Amended) ~~A~~The process for preparation as claimed in claim 7,
wherein the purifying process of the derivatives ~~are~~is purified conducted by column
chromatography.

12. (Currently Amended) A method of treating a ~~diseases condition selected from a~~
~~group comprising cancer, asthma, cardiac hypertrophy, Acquired Immunodeficiency~~
~~Syndrome (AIDS), Human Immunodeficiency Virus (HIV)~~ caused by histone
acetyltransferase (HAT) in a subject in need thereof, wherein said method comprises a
step of administering a pharmaceutically effective amount of the derivatives of
compounds Garcinol or Isogarcinol of

Application Serial Number 10/579219
Response to Office Action dated 01/11/2008




FORMULA I




FORMULA II

Application Serial Number 10/579219
 Response to Office Action dated 01/11/2008



FORMULA I



FORMULA II

respectively to the subject, wherein R1, R2 and R3, substituents of Garcinol, and R4 and R5, substituents of Isogarcinol, are selected from a group comprising consisting of \ominus -Methoxy, \ominus -Ethoxy, \ominus -Isopropoxy, \ominus -Allyloxy, \ominus -Butoxy, \ominus -t-Butoxy, \ominus -Pentoxy, \ominus -Hexyloxy, O-CH₂-COOH, O-CO-CH₂-Cl, O-SO₂-CH₃, and \ominus -O-CH₂-CHOH-CH₃ to the subject.

13. (Currently Amended) ~~A~~The method as claimed in claim 12, wherein the derivatives are ~~histone acetyl transferase (HAT)~~ inhibitors.

14. (New) The process as claimed in claim 7, wherein said halo compounds are selected from a group consisting of halogens and HO $\overline{\text{C}}$ O-CH₂-Cl.

Application Serial Number 10/579219
Response to Office Action dated 01/11/2008

15. (New) The method as claimed in claim 12, wherein the diseases caused by HAT are at least one selected from a group consisting of cancer, asthma, cardiac hypertrophy and acquired immunodeficiency syndrome.